Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an update.
Hangzhou Tigermed Consulting Co., Ltd. announced the election of Mr. Wu Hao as the employee director for the fifth session of its board, following proposed amendments to its Articles of Association. Mr. Wu, who has extensive experience in the pharmaceutical industry, will continue to serve as an executive director and a member of the strategy development committee, enhancing the company’s governance structure and strategic direction.
The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a company based in the People’s Republic of China that operates in the pharmaceutical industry. It provides consulting services and has a focus on strategy development within the sector.
Average Trading Volume: 4,878,203
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.09B
For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.